Mevion Medical Systems today announced that Jay S. Loeffler, MD, has been appointed Co-Chair of Mevion Medical Systems Medical/Technical Advisory Board. Dr. Loeffler, a leading expert in the treatment and management of brain tumors with proton therapy, has been the Chief of the Department of Radiation Oncology at Massachusetts General Hospital (MGH) and Professor of Radiation Oncology and Neurosurgery at Harvard Medical School for over twenty years.

“I’m honored to lead Mevion’s Technical Advisory Board with Dr. Perez. Mevion provides a truly unique innovative technology, and I firmly believe in their mission to improve access to proton therapy for patients who can benefit from the long-term clinical outcomes it can provide,” said Dr. Jay Loeffler. “I look forward to working with the team at Mevion and the Members of our Committee to advance this technology and change the treatment paradigm for patients around the world.”

In this role, Dr. Loeffler will lend his 25 years of experience and insight as the director of the Francis Burr Proton Therapy Center at MGH to help guide Mevion’s clinical and technical development strategy. “I am delighted to welcome Dr. Loeffler to join me for this important role,” said Dr. Carlos Perez, co-chair of Mevion’s Technical Advisory Board. “His substantial expertise on proton therapy will be invaluable to our nine distinguished Board members and the ongoing success of Mevion.”

“The breadth of experience that Dr. Loeffler brings to Mevion will enable us to continue to innovate our unique proton technology and elevate patient care,” said Tina Yu, Ph.D., CEO of Mevion. “We are honored to welcome Dr. Loeffler and look forward to partnering with him as we strive to enable greater access to this transformational treatment modality.”

Prior to his appointments at Massachusetts General Hospital, Dr. Loeffler was an attending physician and founding director of the Brain Tumor Center at Brigham and Women’s Hospital and Dana-Farber Cancer Institute. He is a member of the National Academies of Science, Engineering, and Medicine’s Health and Medical Division and a fellow of the American Society for Radiation Oncology and the American Association for the Advancement of Science. Dr. Loeffler is an author of over 400 publications, a co-editor of 9 books, and has been cited over 37-thousand times. His work helped establish the use of stereotactic radiosurgery (SRS) to treat benign and malignant intracranial tumors and led the way for the use of stereotactic body radiation therapy (SBRT).

About Mevion Medical Systems

Since 2004, Mevion Medical Systems has been the leading provider of compact proton therapy systems for cancer care. Dedicated to advancing the design and accessibility of proton therapy worldwide, Mevion was the first company to innovate this new single-room platform and continues to further the science and application of proton therapy. Mevion’s flagship product, the MEVION S250i Proton Therapy System with HYPERSCAN pencil beam scanning, is the world’s smallest proton therapy system that eliminates the obstacles of size, complexity, and cost that exists with other proton therapy systems. Mevion is headquartered in Littleton, Massachusetts, with a presence in Europe and Asia.

For more information, please visit www.mevion.com.

Follow us on Twitter: @MevionMedical

Connect with us on LinkedIn: Mevion Medical Systems

Like us on Facebook: MevionMedical

View source version on businesswire.com: https://www.businesswire.com/news/home/20210422005404/en/